13F Holdings
中文EN

MDNAF Medicenna Therapeutics Corp. IFRS

Pharmaceutical Preparations · OTC · SEC CIK 1807983 · Reporting currency CAD · Fiscal year ends 03/31

Financial factors as of 2023-03-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY—
TTM net income YoY55.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-39.9%
ROA-33.5%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets19.1%
Debt / equity0.00x
Current ratio9.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: CAD FY2023*2023-03-31FY2022*2022-03-31FY2021*2021-03-31FY2020*2020-03-31
Income statement
Revenue————
R&D expense9.30M14.72M10.87M5.87M
SG&A expense7.00M7.76M6.53M2.38M
Pretax income-10.05M-22.58M-17.29M-8.28M
Income tax0000
Net income-10.05M-22.58M-17.29M-8.28M
EPS (basic)-0.16-0.42-0.35-0.26
EPS (diluted)——-0.35-0.26
Balance sheet
Cash & equivalents33.60M20.54M30.38M22.70M
Current assets36.38M23.39M42.15M37.85M
Intangibles61,00065,00071,00076,000
Total assets36.45M23.46M42.25M38.00M
Current liabilities3.80M2.62M4.11M1.81M
Total liabilities6.96M2.62M4.11M1.85M
Shareholders' equity29.49M20.84M38.15M36.15M
Shares outstanding69.64M55.65M53.55M46.80M
Cash flow statement
Operating cash flow—-23.58M-15.31M-5.42M
Investing cash flow—10.05M5.01M-15.00M
Financing cash flow—3.88M18.26M40.74M
Stock-based compensation—1.42M1.01M1.12M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.